CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Moonlake Immunotherapeutics (MLTX) / sonelokimab
Forward catalyst · MLTX

sonelokimab

Sponsor Moonlake Immunotherapeutics · listed as MLTX

READOUT Phase 3 Confidence: medium Source: clinicaltrials

sonelokimab is a clinical-stage drug asset sponsored by Moonlake Immunotherapeutics, listed as MLTX. CSA tracks 3 forward catalysts for it — the nearest is a readout expected Sep 28, 2026 (day precision, medium confidence), tied to trial NCT06768671. The asset is in Phase 3 and currently active not recruiting, studied in Hidradenitis Suppurativa. It appears across 5 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-09-28
As disclosedSep 28, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06768671
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorMoonLake Immunotherapeutics AG
Listed asMLTX
Condition(s)Hidradenitis Suppurativa

All tracked catalysts for sonelokimab

DateEventConfidenceTrial
2026-09-28READOUTmediumNCT06768671
2027-01-15READOUTmediumNCT06641089
2027-02-04READOUTmediumNCT06641076
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More MLTX catalysts